Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | BRAF V600E |
| Therapy | PLX8394 |
| Indication/Tumor Type | histiocytosis |
| Response Type | predicted - sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| BRAF V600E | histiocytosis | predicted - sensitive | PLX8394 | Case Reports/Case Series | Actionable | In a Phase I/II trial (PLX120-03), PLX8394 treatment resulted in clinical symptom improvement and stable disease ongoing for at least 6.5 years in a young adult patient with recurrent neurodegenerative Langerhans cell histiocytosis harboring BRAF V600E (PMID: 41066726; NCT02428712). | 41066726 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (41066726) | Sustained Response to Pan-BRAF Inhibitor Plixorafenib (FORE8394, PLX8394) in a Young Adult With Neurodegenerative Langerhans Cell Histiocytosis. | Full reference... |